Evidence map›Paper›PMID 41907609›Full record

ArticleFrontiers in oncology2026

Analyzing the effect of neoadjuvant stereotactic ablative body radiotherapy on pancreatic tumor perfusion using computed tomography perfusion.

Jin-Young Bang, Dan Breadner, Timothy Nguyen, Anton Skaro, Chris Goodman, Stephen Welch, Elena Tsvetkova, John Lenehan, Ken Leslie, Ephraim Tang and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Jin-Young BangDepartment of Medical Biophysics, Western University, London, ON, Canada.
Dan BreadnerLondon Health Sciences Centre, London, ON, Canada.
Timothy NguyenLondon Health Sciences Centre, London, ON, Canada.
Anton SkaroLondon Health Sciences Centre, London, ON, Canada.
Chris GoodmanLondon Health Sciences Centre, London, ON, Canada.
Stephen WelchLondon Health Sciences Centre, London, ON, Canada.
Elena TsvetkovaLondon Health Sciences Centre, London, ON, Canada.
John LenehanLondon Health Sciences Centre, London, ON, Canada.
Ken LeslieLondon Health Sciences Centre, London, ON, Canada.
Ephraim TangLondon Health Sciences Centre, London, ON, Canada.
Douglas QuanLondon Health Sciences Centre, London, ON, Canada.
Michael SeyLondon Health Sciences Centre, London, ON, Canada.
Brian YanLondon Health Sciences Centre, London, ON, Canada.
Danielle PorplyciaDepartment of Oncology, London Health Sciences Centre, London, ON, Canada.
James SinfieldDepartment of Oncology, London Health Sciences Centre, London, ON, Canada.
Stewart GaedeLondon Health Sciences Centre, London, ON, Canada.
Ting-Yim LeeDepartment of Medical Biophysics, Western University, London, ON, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: The objective of this study was to investigate the feasibility of administering neoadjuvant stereotactic ablative body radiotherapy (SABR) for the purpose of increasing pancreatic tumor perfusion, hence potentially improving systemic drug delivery in patients with resectable (RPC) or borderline-resectable pancreatic cancer (BRPC). Methods: Neoadjuvant SABR was administered to RPC (n=1) and BRPC (n=5) patients with a dose prescription of 27-30 Gy in 3 fractions and a dose boost up to 45 Gy to the metabolically active areas of the tumor. Computed tomography perfusion (CTP) studies were acquired at baseline, 6 hours after delivering the first SABR fraction (post-1 Results: The post-1 Conclusion: This study provides preliminary evidence that delivering SABR in the neoadjuvant setting for RPC and BRPC patients can induce acute and sustained increases in pancreatic tumor perfusion. Additionally, this study shows that tumor CD may have adequate sensitivity as a biomarker for monitoring patient response to standard-of-care therapy.

Indexed as

computed tomography perfusion (CTP)extravascular extracellular spaceneoadjuvant therapypancreatic ductal adenocarcinoma PDACstereotactic ablative body radiotherapy (SABR)tumor perfusion

Identifiers

PMID41907609
PMCPMC13017369

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.